OBJECTIVE: The aim of the study was to determine whether the chemokine (C-C motif) receptor 5 (CCR5) Delta32 deletion is associated with long-term response to combination antiretroviral treatment (cART) in HIV-1-infected patients. METHODS: The genetic substudy of the Agence Nationale de Recherche sur le SIDA (ANRS) CO8 APROCO-COPILOTE cohort included 609 patients who started protease inhibitor-containing cART in 1997-1999. Patients were considered to have a sustained virological response if all plasma HIV RNA measurements in the period considered were <500 HIV-1 RNA copies/ml, allowing for a single blip. Virological response was compared between patients heterozygous for CCR5 Delta32 (Delta32/wt) and wild-type patients (wt/wt) from month 4 to year 3 and from month 4 to year 5. Logistic regression analysis was used to adjust for baseline demographical data, HIV RNA, CD4 cell count, antiretroviral exposure status, time spent on antiretroviral therapy at years 3 and 5 and adherence to treatment (month 4 to year 3 or 5). RESULTS: A sustained virological response was more frequent in Delta32/wt than in wt/wt patients from month 4 to year 3, with 66%vs. 52% of patients, respectively, showing a sustained response (P=0.02); after adjustment for potential confounders, the association of Delta32 with a sustained response was nearly significant (P=0.07). A sustained virological response was also more frequent in Delta32/wt patients up to year 5, with 48% showing a sustained response vs. 35% of wt/wt patients (P=0.01); after adjustment, Delta32 remained significantly associated with a sustained virological response up to year 5 (P=0.04). There was no association with CD4 response. CONCLUSION: The Delta32 deletion in Delta32/wt patients is associated with a beneficial virological response to cART in the long term. Whether this association is a direct effect of the Delta32 deletion remains unclear and requires confirmation in further observational studies.
OBJECTIVE: The aim of the study was to determine whether the chemokine (C-C motif) receptor 5 (CCR5) Delta32 deletion is associated with long-term response to combination antiretroviral treatment (cART) in HIV-1-infectedpatients. METHODS: The genetic substudy of the Agence Nationale de Recherche sur le SIDA (ANRS) CO8 APROCO-COPILOTE cohort included 609 patients who started protease inhibitor-containing cART in 1997-1999. Patients were considered to have a sustained virological response if all plasma HIV RNA measurements in the period considered were <500 HIV-1 RNA copies/ml, allowing for a single blip. Virological response was compared between patients heterozygous for CCR5 Delta32 (Delta32/wt) and wild-type patients (wt/wt) from month 4 to year 3 and from month 4 to year 5. Logistic regression analysis was used to adjust for baseline demographical data, HIV RNA, CD4 cell count, antiretroviral exposure status, time spent on antiretroviral therapy at years 3 and 5 and adherence to treatment (month 4 to year 3 or 5). RESULTS: A sustained virological response was more frequent in Delta32/wt than in wt/wt patients from month 4 to year 3, with 66%vs. 52% of patients, respectively, showing a sustained response (P=0.02); after adjustment for potential confounders, the association of Delta32 with a sustained response was nearly significant (P=0.07). A sustained virological response was also more frequent in Delta32/wt patients up to year 5, with 48% showing a sustained response vs. 35% of wt/wt patients (P=0.01); after adjustment, Delta32 remained significantly associated with a sustained virological response up to year 5 (P=0.04). There was no association with CD4 response. CONCLUSION: The Delta32 deletion in Delta32/wt patients is associated with a beneficial virological response to cART in the long term. Whether this association is a direct effect of the Delta32 deletion remains unclear and requires confirmation in further observational studies.
Authors: S Guérin; L Meyer; I Theodorou; F Boufassa; M Magierowska; C Goujard; C Rouzioux; P Debré; J F Delfraissy Journal: AIDS Date: 2000-12-01 Impact factor: 4.177
Authors: T E Yamashita; J P Phair; A Muñoz; J B Margolick; R Detels; S J O'Brien; J W Mellors; S M Wolinsky; L P Jacobson Journal: AIDS Date: 2001-04-13 Impact factor: 4.177
Authors: A Mocroft; H Devereux; S Kinloch-de-Loes; D Wilson; S Madge; M Youle; M Tyrer; C Loveday; A N Phillips; M A Johnson Journal: AIDS Date: 2000-07-28 Impact factor: 4.177
Authors: T R O'Brien; D H McDermott; J P Ioannidis; M Carrington; P M Murphy; D V Havlir; D D Richman Journal: AIDS Date: 2000-05-05 Impact factor: 4.177
Authors: J P Ioannidis; P S Rosenberg; J J Goedert; L J Ashton; T L Benfield; S P Buchbinder; R A Coutinho; J Eugen-Olsen; T Gallart; T L Katzenstein; L G Kostrikis; H Kuipers; L G Louie; S A Mallal; J B Margolick; O P Martinez; L Meyer; N L Michael; E Operskalski; G Pantaleo; G P Rizzardi; H Schuitemaker; H W Sheppard; G J Stewart; I D Theodorou; H Ullum; E Vicenzi; D Vlahov; D Wilkinson; C Workman; J F Zagury; T R O'Brien Journal: Ann Intern Med Date: 2001-11-06 Impact factor: 25.391
Authors: Ferdinand W N M Wit; Ronald P van Rij; Gerrit Jan Weverling; Joep M A Lange; Hanneke Schuitemaker Journal: J Infect Dis Date: 2002-11-22 Impact factor: 5.226